These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 35427999)

  • 21. Immune responses to mRNA vaccines against SARS-CoV-2 in patients with immune-mediated inflammatory rheumatic diseases.
    Sieiro Santos C; Calleja Antolin S; Moriano Morales C; Garcia Herrero J; Diez Alvarez E; Ramos Ortega F; Ruiz de Morales JG
    RMD Open; 2022 Jan; 8(1):. PubMed ID: 34987093
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dynamics of SARS-CoV-2 immunity after vaccination and breakthrough infection in rituximab-treated rheumatoid arthritis patients: a prospective cohort study.
    Kared H; Jyssum I; Alirezaylavasani A; Egner IM; The Tran T; Tietze L; Lund KP; Tveter AT; Provan SA; Ørbo H; Haavardsholm EA; Vaage JT; Jørgensen K; Syversen SW; Lund-Johansen F; Goll GL; Munthe LA
    Front Immunol; 2024; 15():1296273. PubMed ID: 38455062
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of Immunosuppression on the Immune Response to SARS-CoV-2 Infection and Vaccination.
    Leacy EJ; Teh JW; O'Rourke AM; Brady G; Gargan S; Conlon N; Scott J; Dunne J; Phelan T; Griffin MD; Power J; Mooney A; Naughton A; Kiersey R; Gardiner M; O'Brien C; Mullan R; Flood R; Clarkson M; Townsend L; O'Shaughnessy M; Dyer AH; Moran B; Fletcher JM; Zgaga L; Little MA;
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791279
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of humoral and cellular immunity induced by the BNT162b2 SARS-CoV-2 vaccine in healthcare workers, elderly people, and immunosuppressed patients with autoimmune disease.
    Malipiero G; Moratto A; Infantino M; D'Agaro P; Piscianz E; Manfredi M; Grossi V; Benvenuti E; Bulgaresi M; Benucci M; Villalta D
    Immunol Res; 2021 Dec; 69(6):576-583. PubMed ID: 34417958
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Humoral and T Cell Response to SARS-CoV-2 Vaccination in Patients With Rheumatoid Arthritis.
    Isnardi CA; Landi M; Cruces L; Maid P; Calle Montoro C; Alfaro MA; Roldán BM; Gómez Vara AB; Giorgis P; Ezquer RA; Crespo Rocha MG; Reyes Gómez CR; Correa MÁ; Cerda OL; Rosemffet MG; Carrizo Abarza V; Catalan Pellet S; Perandones M; Reimundes C; Longueira Y; Turk G; Quiroga MF; Laufer N; De La Vega MC; Citera G; Pons-Estel GJ; Schneeberger EE
    Arthritis Care Res (Hoboken); 2024 Jan; 76(1):120-130. PubMed ID: 37605835
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of different classes of immune-modulating treatments on B cell-related and T cell-related immune response before and after COVID-19 booster vaccination in patients with immune-mediated diseases and primary immunodeficiency: a cohort study.
    Koehm M; Klippstein M; Dauth S; Hallmann K; Kohmer N; Burkhardt H; Ciesek S; Geisslinger G; Rabenau HF; Behrens F
    RMD Open; 2023 Aug; 9(3):. PubMed ID: 37652553
    [TBL] [Abstract][Full Text] [Related]  

  • 27. B-cell repopulation dynamics and drug pharmacokinetics impact SARS-CoV-2 vaccine efficacy in anti-CD20-treated multiple sclerosis patients.
    Asplund Högelin K; Ruffin N; Pin E; Hober S; Nilsson P; Starvaggi Cucuzza C; Khademi M; Olsson T; Piehl F; Al Nimer F
    Eur J Neurol; 2022 Nov; 29(11):3317-3328. PubMed ID: 35808856
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rituximab-to-vaccine interval on SARS-CoV-2 immunogenicity in children: The potential role of prior natural infection.
    Gualtieri R; Yerly S; Garcia-Tarodo S; Parvex P; Rock N; Posfay-Barbe K; Didierlaurent AM; Eberhardt C; Blanchard-Rohner G
    Pediatr Allergy Immunol; 2024 May; 35(5):e14161. PubMed ID: 38796784
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Kinetics of the B- and T-Cell Immune Responses After 6 Months From SARS-CoV-2 mRNA Vaccination in Patients With Rheumatoid Arthritis.
    Farroni C; Picchianti-Diamanti A; Aiello A; Nicastri E; Laganà B; Agrati C; Castilletti C; Meschi S; Colavita F; Cuzzi G; Casetti R; Grassi G; Petrone L; Vanini V; Salmi A; Repele F; Altera AMG; Maffongelli G; Corpolongo A; Salemi S; Di Rosa R; Nalli G; Sesti G; Vaia F; Puro V; Goletti D
    Front Immunol; 2022; 13():846753. PubMed ID: 35309297
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy.
    Marty PK; Van Keulen VP; Erskine CL; Shah M; Hummel A; Stachowitz M; Fatis S; Granger D; Block MS; Duarte-García A; Warrington KJ; Theel ES; Zhou X; Zeng H; Specks U; Escalante P; Peikert T
    Front Immunol; 2022; 13():834981. PubMed ID: 35154159
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Seroconversion among rituximab-treated patients following SARS-CoV-2 vaccine supplemental dose.
    Rose E; Magliulo D; Kyttaris VC
    Clin Immunol; 2022 Dec; 245():109144. PubMed ID: 36220613
    [TBL] [Abstract][Full Text] [Related]  

  • 32. B Cell Characteristics at Baseline Predict Vaccination Response in RTX Treated Patients.
    Stefanski AL; Rincon-Arevalo H; Schrezenmeier E; Karberg K; Szelinski F; Ritter J; Chen Y; Jahrsdörfer B; Ludwig C; Schrezenmeier H; Lino AC; Dörner T
    Front Immunol; 2022; 13():822885. PubMed ID: 35514962
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Humoral and T-cell responses to SARS-CoV-2 vaccination in multiple sclerosis patients treated with ocrelizumab.
    Katz JD; Bouley AJ; Jungquist RM; Douglas EA; O'Shea IL; Lathi ES
    Mult Scler Relat Disord; 2022 Jan; 57():103382. PubMed ID: 35158475
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis.
    Schrezenmeier E; Bergfeld L; Hillus D; Lippert JD; Weber U; Tober-Lau P; Landgraf I; Schwarz T; Kappert K; Stefanski AL; Sattler A; Kotsch K; Dörner T; Sander LE; Budde K; Halleck F; Kurth F; Corman VM; Choi M
    Front Immunol; 2021; 12():690698. PubMed ID: 34276681
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bendamustine impairs humoral but not cellular immunity to SARS-CoV-2 vaccination in rituximab-treated B-cell lymphoma-affected patients.
    Vanni A; Salvati L; Mazzoni A; Lamacchia G; Capone M; Francalanci S; Kiros ST; Cosmi L; Puccini B; Ciceri M; Sordi B; Rossolini GM; Annunziato F; Maggi L; Liotta F
    Front Immunol; 2023; 14():1322594. PubMed ID: 38106404
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.
    Gil-Manso S; Carbonell D; López-Fernández L; Miguens I; Alonso R; Buño I; Muñoz P; Ochando J; Pion M; Correa-Rocha R
    Front Immunol; 2021; 12():726960. PubMed ID: 34671348
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Humoral- and T-Cell-Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies.
    Tortorella C; Aiello A; Gasperini C; Agrati C; Castilletti C; Ruggieri S; Meschi S; Matusali G; Colavita F; Farroni C; Cuzzi G; Cimini E; Tartaglia E; Vanini V; Prosperini L; Haggiag S; Galgani S; Quartuccio ME; Salmi A; Repele F; Altera AMG; Cristofanelli F; D'Abramo A; Bevilacqua N; Corpolongo A; Puro V; Vaia F; Capobianchi MR; Ippolito G; Nicastri E; Goletti D;
    Neurology; 2022 Feb; 98(5):e541-e554. PubMed ID: 34810244
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
    Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
    Front Immunol; 2022; 13():863554. PubMed ID: 35711445
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A prospective multicenter study assessing humoral immunogenicity and safety of the mRNA SARS-CoV-2 vaccines in Greek patients with systemic autoimmune and autoinflammatory rheumatic diseases.
    Tzioufas AG; Bakasis AD; Goules AV; Bitzogli K; Cinoku II; Chatzis LG; Argyropoulou OD; Venetsanopoulou AI; Mavrommati M; Stergiou IE; Pezoulas V; Voulgari PV; Katsimpari C; Katechis S; Gazi S; Katsifis G; Sfontouris CI; Georgountzos AI; Liossis SN; Papagoras C; Fotiadis DI; Skopouli FN; Vlachoyiannopoulos PG; Moutsopoulos HM
    J Autoimmun; 2021 Dec; 125():102743. PubMed ID: 34757289
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
    Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.